Surprised you only give a 10% significantly better rating. I thought the 200 dosage arm showed P being better and thus the 300/400 arms should be definitely better.
Hope you are being extremely conservative in your opinion.
Biohedge -Pretty much in same ball park but agree you are correct about even about same is big home run as they have some bad side effects with celgene product...if it is only about same enough investors may make the mistake that celgene already has market if equal results and give us a chance to catch some cheap stock on dip before it is clearly understood that would be super results and you are right, much better results and it is all over but the shouting..and also first half os sept or with some luck very late august...
You make a strong argument. I differ on one point. IMO there are quite a few other undervalued companies running trials with strong odds of success. Some of these are very near to major inflection points
I'm in here until results with a decent position. I will add on weakness up until results. It's getting dicey for flips but who knows?
Nice post BioHedge, I am still seeing B-OM as the catalyst for us. Prurisol however could be the deal maker though if the results are in the Otezla ballpark.
News 
Market Data 
Discover 
